ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 131 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246 | -87.4% | 22 | -75.8% | 0.00% | – |
| Q2 2023 | $1,947 | +337.5% | 91 | +727.3% | 0.00% | – |
| Q1 2023 | $445 | -75.5% | 11 | -71.8% | 0.00% | – |
| Q4 2022 | $1,814 | +81.4% | 39 | +200.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | -83.3% | 13 | -84.9% | 0.00% | -100.0% |
| Q1 2022 | $6,000 | +500.0% | 86 | +561.5% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 13 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 13 | -45.8% | 0.00% | – |
| Q3 2020 | $1,000 | -66.7% | 24 | -54.7% | 0.00% | -100.0% |
| Q2 2020 | $3,000 | +50.0% | 53 | +60.6% | 0.00% | 0.0% |
| Q1 2020 | $2,000 | – | 33 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
| Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
| ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
| Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
| Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
| Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
| Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
| Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |